Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Akcea Therapeutics
Biotech
Ionis strikes deal to buy back lipid disease spinout Akcea
The deal will see Ionis pay around $500 million to acquire the 24% of Akcea that it doesn’t already own.
Nick Paul Taylor
Aug 31, 2020 8:50am
Akcea, Pfizer hit midphase goal, but data raise doubts
Jan 29, 2020 7:10am
With phase 2 success, Akcea to test triglyceride-buster in FCS
Jan 22, 2020 10:34am
Akcea hands heart drug to Pfizer for $250M
Oct 7, 2019 10:38am
Ex-Ionis/Akcea exec Sarah Boyce takes charge at Avidity
Oct 2, 2019 10:00am
GSK CEO Walmsley joins Microsoft’s board—Chutes & Ladders
Sep 27, 2019 9:30am
